Simultaneous determination of oxacillin and cloxacillin in plasma and CSF using turbulent flow liquid chromatography coupled to high-resolution mass spectrometry: Application in therapeutic drug monitoring.

Bioanalysis High-resolution mass spectroscopy Turbulent flow liquid extraction

Journal

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
ISSN: 1873-376X
Titre abrégé: J Chromatogr B Analyt Technol Biomed Life Sci
Pays: Netherlands
ID NLM: 101139554

Informations de publication

Date de publication:
27 Dec 2023
Historique:
received: 25 09 2023
revised: 13 12 2023
accepted: 17 12 2023
medline: 2 1 2024
pubmed: 2 1 2024
entrez: 31 12 2023
Statut: aheadofprint

Résumé

Cloxacillin and oxacillin are group M penicillins. The therapeutic monitoring of plasma concentrations of these antibiotics and those of their hydroxymethylated metabolites is of great clinical interest, especially in the choice of an adequate dosage allowing an effective treatment while limiting the occurrence of undesirable effects and the development of bacterial resistance. In this context, we conducted this work aiming at developing and validating a method allowing the determination of cloxacillin and oxacillin as well as the identification of their active metabolites in different biological matrices (CSF and plasma) using turbulent flow liquid chromatography coupled to high-resolution mass spectrometry. To do this, we carried out several optimisation tests. Subsequently, we validated our method according to the latest bioanalytical validation recommendations of the European Medicines Agency. The validation results showed that our method is specific and sensitive. We obtained good linearity in the range 0.5 to 100 µg/mL with correlation coefficients above 0.995. The lower limit of quantification was 0.5 µg/mL for each analyte. The method was found to be accurate with repeatability and reproducibility coefficients of variation below 15 %. Our method is also accurate with bias values below 15 %. Recovery values ranged from 87 % to 95 %. Finally, we were able to apply our method to the therapeutic monitoring of the analysed molecules and to identify their active metabolites. Our results suggest that LC-MS shows superiority in the therapeutic monitoring of these antibiotics due to the superiority of specificity shown by this method. This assay method can be routinely used for the daily plasma assays of patients treated with these antibiotics in the context of therapeutic monitoring.

Identifiants

pubmed: 38160527
pii: S1570-0232(23)00389-6
doi: 10.1016/j.jchromb.2023.123979
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

123979

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Sarra Mahfoudhi (S)

Laboratory of Chemical, Galenic and Pharmacological Development of Medicines (LR12ES09), University of Monastir, Faculty of Pharmacy of Monastir, Ibn Sina Street, 5000 Monastir, Tunisia. Electronic address: saramahfoudhi@gmail.com.

Celine Mory (C)

Clinical Microbiology Department and Therapeutic Drug Monitoring Platform, Hospital Group Paris Saint-Joseph, Paris, France.

Jessica Le Ven (J)

Clinical Microbiology Department and Therapeutic Drug Monitoring Platform, Hospital Group Paris Saint-Joseph, Paris, France.

François Coudore (F)

Clinical Microbiology Department and Therapeutic Drug Monitoring Platform, Hospital Group Paris Saint-Joseph, Paris, France; Université Paris-Saclay, UVSQ, CESP, UMR 1018, CESP-Inserm, Faculty of Pharmacy, Orsay, France.

Najoua El Helali (N)

Clinical Microbiology Department and Therapeutic Drug Monitoring Platform, Hospital Group Paris Saint-Joseph, Paris, France.

Fethi Safta (F)

Laboratory of Chemical, Galenic and Pharmacological Development of Medicines (LR12ES09), University of Monastir, Faculty of Pharmacy of Monastir, Ibn Sina Street, 5000 Monastir, Tunisia.

Alban Le Monnier (A)

Clinical Microbiology Department and Therapeutic Drug Monitoring Platform, Hospital Group Paris Saint-Joseph, Paris, France; Institut Micalis, UMR 1319 University Paris Saclay, INRAE, AgroParis Tech, Chatenay-Malabry, France.

Classifications MeSH